Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.
about
Trabectedin for Soft Tissue Sarcoma: Current Status and Future PerspectivesMarine Invertebrate Metabolites with Anticancer Activities: Solutions to the "Supply Problem"Cancer wars: natural products strike backTrabectedin in soft tissue sarcomasTrabectedin and its potential in the treatment of soft tissue sarcoma.Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma.Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone.Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma.Phase I and pharmacokinetic study of trabectedin, a DNA minor groove binder, administered as a 24-h continuous infusion in Japanese patients with soft tissue sarcoma.Role of trabectedin in the treatment of soft tissue sarcomaClinical utility of trabectedin for the treatment of ovarian cancer: current evidence.Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program.Case Report of Suspected Rhabdomyolysis during Treatment with Trabectedin in a Patient with Metastatic LeiomyosarcomaMultidisciplinary management of soft-tissue sarcomas.Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patientsTrabectedin for inoperable or recurrent soft tissue sarcoma in adult patients: a retrospective cohort study.Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary.A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumorsNew drugs and combinations for the treatment of soft-tissue sarcoma: a review.Pharmacodynamic modeling of combined chemotherapeutic effects predicts synergistic activity of gemcitabine and trabectedin in pancreatic cancer cellsA Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens.A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancerTrabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma.Modulation of trabectedin (ET-743) hepatobiliary disposition by multidrug resistance-associated proteins (Mrps) may prevent hepatotoxicityA phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies.Update on the role of trabectedin in the treatment of intractable soft tissue sarcomasWide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives.Trabectedin combined with liposomal doxorubicin in women with relapsed ovarian cancer.Ecteinascidins. A review of the chemistry, biology and clinical utility of potent tetrahydroisoquinoline antitumor antibiotics.In vitro interaction between ecteinascidin 743 (ET-743) and radiation, in relation to its cell cycle effectsTrabectedin for the treatment of breast cancer.The efficacy of trabectedin in treating ovarian cancer.Trabectedin and Eribulin: Where Do They Fit in the Management of Soft Tissue Sarcoma?The safety and efficacy of trabectedin for the treatment of liposarcoma or leiomyosarcoma.Trabectedin for the treatment of soft tissue sarcomas.Chemotherapy for soft tissue sarcoma.Efficacy of trabectedin for the treatment of liposarcoma.Pharmacological therapies for Liposarcoma.Trabectedin has promising antineoplastic activity in high-grade meningioma.PM01183 inhibits myeloid-derived suppressor cells in vitro and in vivo.
P2860
Q26745502-2658ACD6-FD00-4BC7-ADDF-038DA9EFD217Q26746924-B8969D49-6C82-4A6B-9771-18C5C0683873Q26850074-87B448B7-42A5-4748-929F-110838D8B58AQ28085505-DA2D6269-1CF9-455F-9AC2-A83C274612C9Q33380903-33D1D49D-8734-4649-9829-8EA901797D30Q33381641-BC2D78C2-6311-43AF-A9A3-C73F007A979AQ33392364-02D4CDEA-9C1E-49A7-917A-DBD698E3D655Q33428382-3FF03491-AEE7-4826-A890-DB034CB0E053Q33912177-80A24034-5F26-4703-BB2A-837902FBB979Q33916011-49005448-8095-407B-A479-3C86268CF52EQ33921802-16A00873-3AFA-4371-AF5C-F070503F1160Q34578850-9899CB68-1BAC-458E-8CFF-716393BAE3E3Q34629491-2506658D-E9A0-436C-9DE3-BB173DFCC75EQ34798740-E9127750-F27F-477A-9622-38E6E94FEB42Q35676502-15A86B40-2F8A-4F23-BCD0-33DC789A9E1CQ35898258-8DB04F41-8FF0-462B-A52B-D16914B17C90Q35960779-D3ADDEC1-4751-41D6-AA2A-BE493124EDCBQ36233516-DFD3E73F-9B7E-4D81-9015-59588C44E4E2Q36444369-2E750525-BCB7-4AE3-B6F8-046D3F9A0566Q36447737-28AE9951-5A17-4CEE-9DD8-6AF1F3B7C7C7Q36610752-C8810B06-ADC0-4987-9203-4B77FF9B00FBQ36614276-D9EC68C0-4663-486A-968B-103332CF36B2Q36895793-2E4075AB-8FE8-4E05-888A-D6C341AA4EE9Q36948681-2E1AF477-FA1D-42DE-A592-4DC22E98D7E1Q37005569-FC83DBF0-509A-49BE-B775-BCFAA24E162AQ37669484-451A3E88-98CD-4FDE-B2C3-74205B464382Q37760957-BCEDD743-E4BD-48AE-9A98-7EA4844A8039Q37765581-8777672B-FE5A-4EC9-B1BA-955F290BB2BFQ38255906-C8034D20-D215-47D8-BCF4-F0635278AD7FQ38611141-CA2638E4-6F5C-4F18-9AF5-925A830A37F0Q38642314-86AAF90C-FBB0-4E0B-860F-992E19208CF1Q38763841-C83F6E05-7679-4BF9-9C2A-6FC946F6191FQ38769613-25B3E398-F62A-4628-B963-924A8E9660B1Q38797843-319FAC9E-8E83-445B-B204-480BF1D4FB2CQ38872192-52AE772F-2F46-4167-BFF4-01752DAFB666Q38902113-FA3C311C-800D-4833-9E1E-3DD9BBF05291Q38951318-0FD5FE74-DB42-4AED-B82E-2605E749C01EQ38991731-96A74431-60CE-4B01-B8F3-59ABAD688539Q48627774-33ABFD53-C236-4F5D-878E-D58F63374CBFQ50213474-DB937C60-3896-430F-8168-D0DEFFC543C3
P2860
Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Phase I and pharmacokinetic st ...... in patients with solid tumors.
@ast
Phase I and pharmacokinetic st ...... in patients with solid tumors.
@en
type
label
Phase I and pharmacokinetic st ...... in patients with solid tumors.
@ast
Phase I and pharmacokinetic st ...... in patients with solid tumors.
@en
prefLabel
Phase I and pharmacokinetic st ...... in patients with solid tumors.
@ast
Phase I and pharmacokinetic st ...... in patients with solid tumors.
@en
P2093
P1476
Phase I and pharmacokinetic st ...... in patients with solid tumors
@en
P2093
E Cvitkovic
J L Misset
J M Jimeno
P304
P356
10.1200/JCO.2001.19.5.1256
P407
P577
2001-03-01T00:00:00Z